The President has cleared the way for research into new mental-health treatments - but experts urge caution

A new executive order signed by President Donald Trump is speeding up research into psychedelics as a treatment for serious mental health conditions.

President Trump has signed an executive order mandating the FDA and HHS fast-track research into psychedelic drugs to treat mental health conditions, with a focus on veteran care.

Some researchers are delighted at an executive order to streamline investigations of psychedelics but also warn that caution is needed.

The state’s effort will get a boost from the federal government thanks to a new executive order from President Donald Trump.

By Nancy Lapid April 21 (Reuters) - U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research into their use in response to advocates for the drug ibogaine including influential podcaster Joe Rogan.

ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.The order directs acceleration of research and lowered barriers to approvals of psychedelic medications to treat depression,